FindTrial
Sign In

Predictors of future disease activity in non-segmental vitiligo: a prospective cohort study

Clinical, dermoscopic and biomarker predictors of future disease activity in non-segmental vitiligo: a prospective cohort study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/05/087209
Enrollment
100
Registered
2025-05-20
Start date
Unknown
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L80- Vitiligo

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

AIIMS, New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adult patients with stable (no new lesions or increase in size of pre-existing lesions in the last 3 months or more) / repigmenting non-segmental (generalized or acrofacial) vitiligo of any extent, irrespective of ongoing local treatment (including topical immunomodulators, topical photochemotherapy, hand-held NbUVB, excimer light), and off-systemic treatments or whole body phototherapy for at-least 4 weeks

Exclusion criteria

Exclusion criteria: Patients with active vitiligo (in the last 3 months) or unsure disease course Patients with stable non-segmental vitiligo of less than 3 months Patients on systemic treatment or phototherapy in the last 4 weeks Pregnant or lactating females Patients with concurrent skin or systemic inflammatory disease

Design outcomes

Primary

MeasureTime frame
1.To identify serum biomarkers to predict future disease activity in patients with stable/repigmenting non-segmental vitiligo at 3-12 months follow-upTimepoint: 0, 3, 6, 9, 12 months—

Secondary

MeasureTime frame
1. To identify tissue biomarkers to predict future patch activity in patients with stable/repigmenting non-segmental vitiligo at 3-12 months follow-up 2. To identify dermoscopic features to predict future patch activity in patients with stable/repigmenting non-segmental vitiligo at 3-12 months follow-up 3. To identify clinical features to predict future disease activity in patients with stable/repigmenting non-segmental vitiligo at 3-12 months follow-up 4. To assess the longitudinal change in serum biomarkers 5. To correlate serum biomarkers with vitiligo extent, type and activity 6. To compare tissue biomarkers between acral and non-acral vitiligo patches Timepoint: 0, 3, 6, 9, 12 months—

Countries

India

Contacts

Public ContactVishal Gupta

All India Institute of Medical Sciences

someshgupta@aiims.edu9868899120

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026